BR112023011605A2 - Uso do peptídeo, método de tratamento de câncer ou infecções virais, e, combinação farmacêutica - Google Patents
Uso do peptídeo, método de tratamento de câncer ou infecções virais, e, combinação farmacêuticaInfo
- Publication number
- BR112023011605A2 BR112023011605A2 BR112023011605A BR112023011605A BR112023011605A2 BR 112023011605 A2 BR112023011605 A2 BR 112023011605A2 BR 112023011605 A BR112023011605 A BR 112023011605A BR 112023011605 A BR112023011605 A BR 112023011605A BR 112023011605 A2 BR112023011605 A2 BR 112023011605A2
- Authority
- BR
- Brazil
- Prior art keywords
- peptide
- cancer
- drug
- viral infections
- pharmaceutical combination
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 5
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 3
- 208000036142 Viral infection Diseases 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 230000000259 anti-tumor effect Effects 0.000 abstract 3
- 230000000840 anti-viral effect Effects 0.000 abstract 3
- 229940079593 drug Drugs 0.000 abstract 3
- 239000003814 drug Substances 0.000 abstract 3
- 230000036039 immunity Effects 0.000 abstract 3
- 230000037449 immunogenic cell death Effects 0.000 abstract 2
- 230000001404 mediated effect Effects 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000001024 immunotherapeutic effect Effects 0.000 abstract 1
- 238000009169 immunotherapy Methods 0.000 abstract 1
- 230000006698 induction Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Endocrinology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
uso de peptídeo sintético para a indução de imunidade antitumor e antiviral. uso do peptídeo identificado como seq id no: 1 para fabricar um fármaco que induz imunidade antitumoral e antiviral mediada por morte celular imunogênica. a invenção também provê um método para tratar câncer ou infecções virais, distinguido pelo fato de que administra, a um indivíduo que precisa deste, uma quantidade terapeuticamente eficaz de um fármaco para a indução de imunidade antitumoral e antiviral mediada por morte celular imunogênica, o fármaco compreendendo o dito peptídeo sintético. a invenção também se refere a uma combinação farmacêutica compreendendo o peptídeo identificado como seq id no: 1 e uma vacina para imunoterapia contra o câncer, que resulta em uma abordagem imunoterapêutica mais eficaz para esta doença.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CU2020000103A CU20200103A7 (es) | 2020-12-18 | 2020-12-18 | Péptido sintético para la inducción de inmunidad antitumoral y antiviral |
PCT/CU2021/050013 WO2022127945A2 (es) | 2020-12-18 | 2021-11-23 | Uso de péptido sintetico para la induccion de inmunidad antitumoral y antiviral |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112023011605A2 true BR112023011605A2 (pt) | 2023-10-31 |
Family
ID=80683707
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112023011605A BR112023011605A2 (pt) | 2020-12-18 | 2021-11-23 | Uso do peptídeo, método de tratamento de câncer ou infecções virais, e, combinação farmacêutica |
Country Status (11)
Country | Link |
---|---|
US (1) | US20240082392A1 (pt) |
EP (1) | EP4265268A2 (pt) |
JP (1) | JP2023554401A (pt) |
KR (1) | KR20230122063A (pt) |
CN (1) | CN116963758A (pt) |
AU (1) | AU2021403339A1 (pt) |
BR (1) | BR112023011605A2 (pt) |
CA (1) | CA3201752A1 (pt) |
CU (1) | CU20200103A7 (pt) |
MX (1) | MX2023007293A (pt) |
WO (1) | WO2022127945A2 (pt) |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CU23225A1 (es) * | 2001-12-20 | 2007-08-30 | Ct Ingenieria Genetica Biotech | PéPTIDOS PARA EL TRATAMIENTO DEL CáNCER ASOCIADO AL VIRUS PAPILOMA HUMANO (VPH) Y DE OTROS TUMORES EPITELIALES |
CU23511B6 (es) * | 2006-02-28 | 2010-04-13 | Biorec B V | Combinación farmacéutica para el tratamiento y/o quimiosensibilización de tumores refractarios a drogas anticancerígenas |
-
2020
- 2020-12-18 CU CU2020000103A patent/CU20200103A7/es unknown
-
2021
- 2021-11-23 AU AU2021403339A patent/AU2021403339A1/en active Pending
- 2021-11-23 JP JP2023536436A patent/JP2023554401A/ja active Pending
- 2021-11-23 WO PCT/CU2021/050013 patent/WO2022127945A2/es active Application Filing
- 2021-11-23 EP EP21865362.4A patent/EP4265268A2/en active Pending
- 2021-11-23 CA CA3201752A patent/CA3201752A1/en active Pending
- 2021-11-23 KR KR1020237023660A patent/KR20230122063A/ko active Search and Examination
- 2021-11-23 BR BR112023011605A patent/BR112023011605A2/pt unknown
- 2021-11-23 US US18/268,118 patent/US20240082392A1/en active Pending
- 2021-11-23 MX MX2023007293A patent/MX2023007293A/es unknown
- 2021-11-23 CN CN202180093881.4A patent/CN116963758A/zh active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2022127945A3 (es) | 2022-12-22 |
WO2022127945A2 (es) | 2022-06-23 |
EP4265268A2 (en) | 2023-10-25 |
JP2023554401A (ja) | 2023-12-27 |
CA3201752A1 (en) | 2022-06-23 |
CU20200103A7 (es) | 2022-07-08 |
KR20230122063A (ko) | 2023-08-22 |
US20240082392A1 (en) | 2024-03-14 |
AU2021403339A1 (en) | 2023-07-06 |
CN116963758A (zh) | 2023-10-27 |
MX2023007293A (es) | 2023-07-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2023014569A (es) | Anticuerpos anti-sirpa. | |
BR112018068748A2 (pt) | composto, composição farmacêutica e de vacina, métodos para indução ou promoção de uma resposta imunológica, para tratamento de câncer, de doenças infecciosas, de distúrbios imunológicos e de doenças imunológicas e para tratamento ou prevenção de uma doença, e, uso de um composto | |
BR112017017949A2 (pt) | regimes de iniciação-reforço envolvendo administração de pelo menos um constructo de mrna | |
PE20211270A1 (es) | Anticuerpos anti-pd-1 y metodos de tratamiento | |
DOP2017000175A (es) | Dinucleótidos cíclicos útiles en el tratamiento del cáncer | |
BR112017003108A2 (pt) | anticorpo ou fragmento de ligação a antígeno do mesmo, polipeptídeo isolado, ácido nucleico isolado, vetor de expressão, célula hospedeira, composição, métodos para produção de um anticorpo ou fragmento de ligação a antígeno, para tratamento de câncer e de uma infecção ou doença infecciosa, para detecção da presença de um peptídeo de tigit ou um fragmento do mesmo e para aumentar a atividade de uma célula imune e a atividade antitumoral de um anticorpo anti-tigit, vacina, e, uso de um anticorpo ou fragmento de ligação a antígeno | |
BR112014021101A2 (pt) | Anticorpo, composição farmacêutica, droga de combinação, dna e método de tratamento e/ou prevenção de câncer, uso de um anticorpo | |
EA201791535A1 (ru) | Новое соединение 4'-тионуклеозида, а также способ его получения, его фармацевтическая композиция и применение | |
CO2023018231A2 (es) | Restos de administración terapéutica novedosos y usos de estos | |
AR101871A1 (es) | Composiciones de glicoconjugado inmunogénico / terapéutico y sus usos | |
CL2019000722A1 (es) | Nueva vacuna contra la gripe porcina. | |
AR099068A1 (es) | Anticuerpo anti-netrina-1 | |
ZA202202174B (en) | Method for treating diseases based on interferon | |
CY1123639T1 (el) | Μονοκλωνα ολιγονουκλεοτιδια για χρηση στην ιατρικη θεραπευτικη αντιμετωπιση διαταραχων του δερματος | |
AR112166A1 (es) | Composiciones terapéuticas y métodos para el tratamiento de hepatitis b | |
MX2021015235A (es) | Compuestos utiles para el tratamiento de una infeccion por mannheimia haemolytica o histophilus somni. | |
ZA202107428B (en) | Porcine circovirus type 3 (pcv3) vaccines, and production and uses thereof | |
CY1123449T1 (el) | Mini δισκια μελατονινης και μεθοδος παρασκευης αυτων | |
BR112022000710A2 (pt) | Vacina viral terapêutica | |
CO2022011183A2 (es) | Conjugados de proteínas-compuestos antivirales | |
CO2020004984A2 (es) | Proceso para preparar el benzotiofen-2-il boronato | |
MX2021010766A (es) | Anticuerpos que se unen a la proteína del gen 6 inducible por el factor de necrosis tumoral (tsg-6) y usos de estos. | |
EA202191145A1 (ru) | Вакцина виб 4/91 с гетерологичным шиповидным белком | |
BR112023011605A2 (pt) | Uso do peptídeo, método de tratamento de câncer ou infecções virais, e, combinação farmacêutica | |
BR112019005825A2 (pt) | vírus envelopado modificado, composição farmacêutica, e, método para tratar um câncer |